论文部分内容阅读
目的:探讨新辅助化疗对Ib2～IIb期宫颈癌的疗效。方法:选择2008年1月～2012年4月经病理确诊的36例Ib2～IIb期宫颈癌患者给予紫杉醇加卡铂1～3个疗程化疗,评估疗效显著者行手术治疗。结果:化疗后肿瘤直径多数均有不同程度的缩小,有效率达75%,大多数患者能手术治疗切除病灶,仅少数患者无法行手术治疗。结论:术前新辅助化疗对宫颈癌Ib2～IIb期治疗安全有效,缩小肿瘤体积,提高手术切除率及疗效,为无法手术的患者创造手术可能,为治疗该病的有效治疗手段。
Objective: To investigate the effect of neoadjuvant chemotherapy on patients with stage Ib2 ~ IIb cervical cancer. Methods: Thirty-six patients with pathologically confirmed cervical cancer from January 2008 to April 2012 were treated with 1 or 3 courses of chemotherapy with paclitaxel and carboplatin, and the patients with significant curative effect were evaluated by surgery. Results: Most of the tumor diameters after chemotherapy were reduced to varying degrees, the effective rate of 75%, most patients with surgical resection of lesions, only a small number of patients can not be surgically treated. Conclusions: Preoperative neoadjuvant chemotherapy is safe and effective for the treatment of patients with stage Ib2 ~ IIb cervical cancer, which can reduce the tumor volume, improve the resection rate and curative effect, create the possibility of surgery for patients who can not operate, and effectively treat the disease.